Indian Pharma Company Invested in Belarusian Manufacturing Project

| By | Belarusian Pharma, Indian Pharma

Indian pharmaceutical company Cipla Limited has invested $1 million in the pharmaceutical manufacturing project in Minsk. The project was discussed by Chairman of the Presidium of the National Academy of Sciences of Belarus (NASB) Vladimir Gusakov and Dr. Lalit Chokhani, Belarus’ Honorary Consul in India, on 14 May.

The parties discussed cooperation prospects and promising collaboration mechanisms between the NASB and Cipla Limited, establishment of an R&D center to produce innovative solid medicines on the premises of the Academpharm company affiliated with the NASB. “The Indian partners have already invested $1 million in this project. The new production facility will use innovative technological solutions, like micronization, dry granulation, production of multilayer tablets, and other methods. There will be a full-cycle production, from an idea to manufacturing,” the press service noted.

An arrangement has been reached to localize the production of certain medicines in the territory of Belarus. These are medicines to treat life-threatening diseases, like HIV, hepatitis B and C, as well as drugs to treat Alzheimer’s disease and pulmonary arterial hypertension. The work on the architectural design of the production facility is in full swing.

Belarus’ delegation visited India in September 2017. Following the visit the Belarusian president issued a protocol of instructions providing for the transfer of technology to produce medicines jointly with Cipla Limited and for the launch of a full-cycle production on the Academpharm premises by 31 December 2020. In order to take inventory of the project, a Cipla Limited delegation will come to Minsk in July 2019. The delegation will be led by Non-Executive Chairman of the company and honorary member of the NASB Yusuf Khwaja Hamied.

The collaboration between Cipla Limited and Academpharm in contract manufacturing of medicines started back in 2016.

Founded in 1935, Cipla Limited is focused on development, chemical synthesis and production of over 1,500 ready-made medications of various forms. It offers antitumor medicines, bronchodilators, corticosteroids, immunosuppressants, chemotherapeutic and antiretroviral agents, antibiotics, antidepressants and other medicines. Cipla Limited is present in 150 countries across the globe.

SOURCE: belta
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.